Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2021 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 61 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Asterion Therapeutics from Beveren-Kruibeke-Zwijndrecht, company number BE0715602553, closed financial year 2025 with a result of € -95,406 after tax. For that financial year Asterion Therapeutics recorded a gross margin of € -15,448 and equity of € -214,025. Compared with financial year 2021, the result moved from € -25,842 to € -95,406. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ -214,025
▼ € 128,855 vs 2021
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -95,406
▼ 269 % more loss than in 2021
Profit after tax over the fiscal year.
€ 151
▼ 67% vs 2021
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -259,025.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
€ 161,531
▲ 80% vs 2021
Loans from banks and other lenders, long and short.
€ 30,564
▼ 3% vs 2021
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2025 | Change 2021 → 2025 | |
|---|---|---|---|
| Gross margin | € -17,865 | € -15,448 | ▲ € 2,417 |
| Profit after taxes | € -25,842 | € -95,406 | ▼ € 69,563 |
| Equity | € -85,170 | € -214,025 | ▼ € 128,855 |
| Total debts | € 121,352 | € 197,489 | ▲ 63% |
| Cash | € 463 | € 151 | ▼ 67% |
| Retained profit | € -111,990 | € -259,025 | ▼ € 147,035 |
| Bank debt | € 89,511 | € 161,531 | ▲ 80% |
| Balance sheet total | € 36,181 | € 58,464 | ▲ 62% |
Key figures of Asterion Therapeutics, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Asterion Therapeutics?
What happened at Asterion Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 95,406. filed late Source: NBB ↗
- New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
- Start of the company according to the CBE. KBO
In short
From € 25,842 loss in 2021 to € 95,406 loss in 2025.
A new publication or filing at Asterion Therapeutics? We notify you, reason included.
Follow Asterion TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Perpetuum Ventures comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Asterion TherapeuticsBehind Asterion Therapeutics is James Troch. The shares are held by Perpetuum Ventures (49.5%).
Directors
According to the 2025 annual accounts
James Troch
Director
Also active at: DIGITAL DARWIN, VENTURE CAMPUS, 247 Energy, Perpetuum Ventures, Perpetuum CropScience, Deep Medicine, 247 Alpha, d2 benelux +1 more
Shareholders
49.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Schaarbeekstraat(MEL) 20D box 1
9120 Beveren-Kruibeke-Zwijndrecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0715.602.553
- VAT number
- BE 0715.602.553
- Registered office
- Schaarbeekstraat(MEL) 20D bus 1, 9120 Beveren-Kruibeke-Zwijndrecht
- Names & denominations
- Asterion Therapeutics · Asterion
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 December 2018
- Peppol
- Active · Active since 15 Apr 2026
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Vervaardiging van parfums en toiletartikelen
Overige detailhandel in voedingsmiddelen, neg
Vervaardiging van andere voedingsmiddelen, neg
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.